# Pizarra — PT-pseudo_3ceacc9b660b (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_3ceacc9b660b
Task: 1

Encounter: Urology - outpatient on 23 Feb 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 58-year-old male
  - PSA: 6.0 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.13 ng/mL²
  - PSA velocity: 0.34 ng/mL/yr
  - Prior PSA: 5.4 ng/mL
  - Prostate volume: 49.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7948016 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension
  - Problem list / PMHx: Hypertension
  - Current medication: amlodipine, lisinopril, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 6 ng/mL. PI-RADS 3. PSAD 0.13. Prostate volume 49 mL. csPCa 0.79.

Vitals: weight 60 kg, height 178 cm, BMI 18.9, BP 125/74 mmHg, HR 70 bpm. Smoking: Non-smoker.

Chief complaint: Persistent elevation of prostate-specific antigen combined with prior histological confirmation of low-grade malignancy necessitates clinical reassessment.

History: Mr. X is a 58-year-old retired mechanical engineer who lives in a multi-generational home with his spouse and adult daughter. A non-smoker, he maintains an alcohol-free lifestyle and performs chair-based exercises to accommodate limited mobility. Urinary complaints are minimal, scoring 2 out of 35 on the IPSS. His medical background includes hypertension, currently managed with amlodipine, lisinopril, and metoprolol. Additional historical points feature a stable HbA1c of 6.4%, a remote appendectomy during his thirties, and a recent vascular surgery consultation for varicose veins, with no accompanying systemic complaints or bone pain.

Physical examination: DRE: The prostate exhibits a symmetric enlargement characterized by a smooth, firm consistency. Palpation identifies no nodules or asymmetrical areas. General survey shows stable vital signs, an unremarkable abdominal exam, and no palpable lymphadenopathy.

Patient info: retired mechanical engineer; Married; Lives with adult child (multi-generational household).
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Limited mobility — chair-based exercises only; IPSS score: 2/35 (mild LUTS).

Recent other appointments: Vascular surgery — varicose veins consult.
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.43 +/- 0.19   (95% CI 0.10-0.81)

Where the uncertainty comes from:
  - aleatoric  dA = 0.16  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 6.4 effective neighbours out of 10; 2 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=3.0, bx_ord=3.0, psa=6.0, age=58.0, psad=0.13, dre_ord=0.0, vol=49.0, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered static variables (PI-RADS 3, PSA 6.0, prior positive biopsy) and failed to weigh the dynamic information such as the PSA velocity (0.34 ng/mL/yr) or the specific PSA density (0.13 ng/mL²). It did not account for the clinical context that a prior positive biopsy means the question shifts from "does he have cancer?" to "is the existing cancer progressing or is the MRI lesion evolving?"

WHY THE SUGGESTION COULD BE WRONG
The prior suggested "NO BIOPSY" with a wide uncertainty interval (0.10-0.81). This wide interval suggests the classifier is genuinely unable to distinguish between biopsy and no biopsy based on the limited input. Specifically, the prior fails to account for the fact that a rising PSA (6.0 from 5.4) combined with a PI-RADS 3 lesion warrants re-evaluation, which is a clinical signal the prior cannot interpret. Furthermore, the prior does not account for the guideline criterion that the decision hinges on the retrieved MRI report and the prior biopsy status.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes - context regarding the prior positive diagnosis
laboratory panel - full panel
family-history of prostate cancer (anamnesis)

GUIDELINE ANCHOR
The guideline suggests that the decision must be based on whether the prior grade is documented, whether the lesion changed against a previous MRI, and whether surveillance re-biopsy is due.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI Report: Erasmus MC University Medical Center | 15 Feb 2025 | Multiparametric MRI Prostate. T2 sequences highlight a 12 mm hypointense focus within the right mid-gland peripheral zone. Diffusion-weighted sequences exhibit moderately restricted diffusion paired with low ADC values, falling short of definitive malignancy. Extracapsular extension and suspicious lymphadenopathy are absent. PI-RADS 3.

get_psa_trend
PSA Trend: [{"date": "Dec 2023", "val": 1.2}, {"date": "Apr 2024", "val": 2.1}, {"date": "Sep 2024", "val": 3.5}, {"date": "Feb 2025", "val": 6.0}]

get_previous_notes
Previous Notes: 26 Oct 2024 - Dr. R. van den Berg (GP): PSA climbed to 5.4 ng/mL after a plateau, triggering a urology referral for re-assessment given the earlier positive biopsy. 29 Feb 2024 - Dr. R. van den Berg (GP): A PSA measurement of 4.8 ng/mL indicated a slight quarterly decline.

get_lab_results
Lab Results: PSA 6.0 ng/mL (07 Feb 2025). %Free PSA 24% (07 Feb 2025).

NOT RETRIEVED
Family history of prostate cancer anamnesis was not retrieved, which is not required for this decision.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling:
- PSA velocity is positive, with a rise from 3.5 ng/mL (Sep 2024) to 6.0 ng/mL (Feb 2025).
- The MRI shows a 12 mm hypointense focus with moderately restricted diffusion, which is equivocal (PI-RADS 3).

AGAINST Sampling:
- Prior biopsy was positive (no documented grade).
- The MRI finding is PI-RADS 3, suggesting low-to-intermediate risk.

WHERE THIS LEANS
The evidence suggests a need for further investigation due to the rising PSA and equivocal MRI finding, which aligns with the guideline criterion that the decision hinges on the MRI report and prior biopsy status. This leans toward a re-biopsy or further characterization.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

Although the patient has a prior positive biopsy, the rising PSA from 5.4 to 6.0 ng/mL and the equivocal PI-RADS 3 finding on the MRI warrant further investigation. Since no documented ISUP grade or comparison against a previous MRI is present, the decision hinges on the retrieved evidence suggesting progression or evolution of the lesion. Therefore, a re-biopsy is recommended to determine if the existing cancer has progressed, which is a clear indication for sampling.

Variables that carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
